These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27389084)

  • 21. Lorcaserin: a review of its use in chronic weight management.
    Hoy SM
    Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
    Hollander P; Lasko B; Barnett AH; Bengus M; Kanitra L; Pi-Sunyer FX; Balena R
    Obesity (Silver Spring); 2013 Feb; 21(2):238-47. PubMed ID: 23404788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
    Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
    Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studies.
    Fujioka K; Malhotra M; Perdomo C; Apovian CM
    Obes Sci Pract; 2019 Apr; 5(2):120-129. PubMed ID: 31019729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet.
    Shaw Tronieri J; Wadden TA; Berkowitz RI; Chao AM; Pearl RL; Alamuddin N; Leonard SM; Carvajal R; Bakizada ZM; Pinkasavage E; Gruber KA; Walsh OA; Alfaris N
    Obesity (Silver Spring); 2018 Feb; 26(2):299-309. PubMed ID: 29288545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
    Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
    Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population.
    Lu CW; Chang CJ; Yang YC; Lin WY; Huang KC
    Obes Res Clin Pract; 2018 Jul; 12(5):465-471. PubMed ID: 30033356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
    Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
    Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Hanefeld M; Sachse G
    Diabetes Obes Metab; 2002 Nov; 4(6):415-23. PubMed ID: 12406041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
    Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP;
    Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials.
    Weissman NJ; Smith SR; Fain R; Hall N; Shanahan WR
    Obesity (Silver Spring); 2017 Jan; 25(1):39-44. PubMed ID: 27888609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.